Detaljert visning patent

Nettleseren støtter ikke Javascript. Javascript må være aktivert for å bruke denne tjenesten. Vennligst kontakt din IT-ansvarlige.

Nøkkelinformasjon chevron_right

Viktig informasjon i saken hentes i sanntid direkte fra EPO sitt register (European Patent Register), slik at du enkelt og raskt får oversikt i saken.
Beskrivelse	Verdi
Saken / databasen er sist oppdatert	2025.04.19 12:25:00 info
Tittel	METHODS FOR TREATING HUNTINGTON'S DISEASE
Status Hovedstatus Detaljstatus	Ikke i kraft info 2024.06.20 Patent opphørt 2024.06.26 Oversettelse av endret EP patent (B2/B3) ikke innlevert
Patentnummer	NO/EP3386511
Europeisk (EP) publiserings nummer	EP3386511
EP levert	2016.12.11
EP søknadsnummer	16874024.9
EP meddelt	2021.05.12
Prioritet	2015.12.10, US 201562265652 P
Sakstype	Europeisk
Løpedag	2016.12.11
Utløpsdato	2036.12.11
Allment tilgjengelig	2018.10.17
Validert i Norge	2021.09.06
Innehaver	PTC Therapeutics, Inc. (US)
Oppfinner	BABU, Suresh (US) .... se mer/flere nedenfor
Fullmektig	BRYN AARFLOT AS (NO)
Lenke til European patent Register	Informasjon i saken, dokumenter og patentfamilie
Patentfamilie	Se i Espacenet

Sammendrag og figur chevron_right

Se forsidefigur og sammendrag i Espacenet

Beskrivelse og krav chevron_right

Beskrivelse

Krav

Patentkrav

1. Forbindelse for anvendelse ved behandling eller forbedring av Huntingtons sykdom (HD) hos et individ med behov derav, hvor forbindelsen skal administreres til individet i en effektiv mengde, hvor forbindelsen har formel (Ia):

eller en form derav, hvor

X er CH2, O, NR5 eller en binding;

A er aryl, heteroaryl, heterocyklyl eller C9-10cykloalkyl, hvor:

aryl er valgt fra:

i) fenyl substituert med hydroksyl og eventuelt 1, 2 eller 3 ytterligere substituenter, hvor de ytterligere substituentene er hver valgt fra gruppen bestående av R1 og hydroksyl, og ii) naftyl eventuelt substituert med 1, 2, 3 eller 4 substituenter, hvor substituentene er hver valgt fra gruppen bestående av R1 og hydroksyl,

heteroaryl er valgt fra gruppen bestående av furanyl, tienyl, pyrrolyl, pyrazolyl, imidazolyl, isoksazolyl, isotiazolyl, oksazolyl, tiazolyl, triazolyl, oksadiazolyl, tiadiazolyl, tetrazolyl, pyranyl, tiopyranyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, indolyl, indazolyl, indolizinyl, benzofuranyl, benzotienyl, benzimidazolyl, benzotiazolyl, benzooksazolyl, 9H-purinyl, kinoksalinyl, isoindolyl, kinolinyl, isokinolinyl, kinazolinyl, akridinyl, ftalazinyl, imidazo[1,2-a]pyridinyl, imidazo[1,5-a]pyridinyl, imidazo[5,1-a]isokinolinyl, 1,4-dihydroindeno[1,2-c]-1H-pyrazolyl, 2,3-dihydro-1H-inden-1-on, 2,3-dihydro-1H-indenyl, 3,4-dihydrokinolin-2(1H)-on, 5,6-dihydroimidazo[5,1-a]isokinolinyl, 8H-indeno[1,2-d]tiazolyl, benzo[c][1,2,5]oksadiazolyl, benzo[d]oksazol-2(3H)-on, kinolin-2(1H)-on, kinazolin-4(1H)-on, kinazolin-2,4(1H,3H)-dion, benzo-[d]oksazolyl og pyrazolo[1,5-a]pyridinyl, hvor heteroaryl eventuelt er substituert med 1, 2, 3, 4 eller 5 substituenter hver valgt fra R1,

heterocyklyl er valgt fra gruppen bestående av oxiranyl, oxetanyl, azetidinyl, dihydrofuranyl, tetrahydrofuranyl, dihydrotienyl, tetrahydrotienyl, pyrrolinyl, pyrrolidinyl, dihydropyrazolyl, pyrazolinyl, pyrazolidinyl, dihydroimidazolyl, imidazolinyl, imidazolidinyl, isoksazolinyl, isoksazolidinyl, isotiazolinyl, isotiazolidinyl, oksazolinyl, oksazolidinyl, tiazolinyl, tiazolidinyl, triazolinyl, triazolidinyl, oksadiazolinyl, oksadiazolidinyl, tiadiazolinyl, tiadiazolidinyl, tetrazolinyl, tetrazolidinyl, dihydro-2H-pyranyl, dihydro-pyridinyl,

tetrahydro-pyridinyl, 1,2,3,6-tetrahydropyridinyl, heksahydro-pyridinyl, dihydro-pyrimidinyl, tetrahydro-pyrimidinyl, 1,4,5,6-tetrahydropyrimidinyl, dihydro-pyrazinyl, tetrahydro-pyrazinyl, dihydro-pyridazinyl, tetrahydro-pyridazinyl, piperazinyl, piperidinyl, morfolinyl, tiomorfolinyl, dihydro-triazinyl, tetrahydro-triazinyl, heksahydro-triazinyl, 1,4-diazepanyl, dihydro-indolyl, indolinyl, tetrahydro-indolyl, dihydro-indazolyl, tetrahydro-indazolyl,

dihydro-isoindolyl, dihydro-benzofuranyl, tetrahydro-benzofuranyl, dihydro-benzotienyl, tetrahydro-benzotienyl, dihydro-benzimidazolyl, tetrahydro-benzimidazolyl, dihydro-benzooksazolyl, 2,3-dihydrobenzo[d]oksazolyl, tetrahydro-benzooksazolyl,

dihydro-benzooksazinyl, 3,4-dihydro-2H-benzo[b][1,4]oksazinyl, tetrahydro-benzooksazinyl, benzo[1,3]dioksolyl, benzo[1,4]dioksanyl, dihydro-purinyl, tetrahydro-purinyl, dihydro-kinolinyl,

tetrahydro-kinolinyl, 1,2,3,4-tetrahydrokinolinyl, dihydro-isokinolinyl, 3,4-dihydroisokinolin-(1H)-yl, tetrahydro-isokinolinyl, 1,2,3,4-tetrahydroisokinolinyl, dihydro-kinazolinyl, tetrahydro-kinazolinyl, dihydro-kinoksalinyl, tetrahydro-kinoksalinyl, 1,2,3,4-tetrahydrokinoksalinyl, 1,3-dioksolanyl, 2,5-dihydro-1H-pyrrolyl, 4,5-dihydro-1H-imidazolyl, tetrahydro-2H-pyranyl, heksahydropyrrolo[3,4-b][1,4]oksazin-(2H)-yl, (4aR,7aS)-heksahydropyrrolo[3,4-b][1,4]oksazin-(4aH)-yl, 3,4-dihydro-2H-pyrido[3,2-b][1,4]oksazinyl, (cis)-oktahydrocyklopenta[c]pyrrolyl, heksahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-heksahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aS)-heksahydropyrrolo[3,4-c]pyrrol-(1H)-yl, 5H-pyrrolo[3,4-b]pyridin-(7H)-yl, 5,7-dihydro-6H-pyrrolo[3,4-b]pyridinyl, tetrahydro-1H-pyrrolo[3,4-b]pyridin-(2H,7H,7aH)-yl, heksahydro-1H-pyrrolo[3,4-b]pyridin-(2H)-yl, (4aR,7aR)-heksahydro-1H-pyrrolo[3,4-b]pyridin-(2H)-yl, oktahydro-6H-pyrrolo[3,4-b]pyridinyl, 2,3,4,9-tetrahydro-1H-karbazolyl, 1,2,3,4-tetrahydropyrazino[1,2-a]indolyl, 2,3-dihydro-1H-pyrrolo[1,2-a]indolyl, (3aR,6aR)-heksahydrocyklopenta[c]pyrrol-(1H)-yl, (3aR,4R,6aS)-heksahydrocyklopenta[c]pyrrol-(1H)-yl, (3aR,4S,6aS)-heksahydrocyklopenta[c]pyrrol-(1H)-yl, (3aR,5r,6aS)-heksahydrocyklopenta[c]pyrrol-(1H)-yl, 1,3-dihydro-2H-isoindolyl, oktahydro-2H-isoindolyl, (3aS)-1,3,3a,4,5,6-heksahydro-2H-isoindolyl, (3aR,4R,7aS)-1H-isoindol-(3H,3aH,4H,5H,6H,7H,7aH)-yl, (3aR,7aS)-oktahydro-2H-isoindolyl, (3aR,4R,7aS)-oktahydro-2H-isoindolyl, (3aR,4S,7aS)-oktahydro-2H-isoindolyl, 2,5-diazabicyklo[2,2,1]heptanyl, 2-azabicyklo[2,2,1]heptenyl, 3-azabicyklo[3,1,0]heksanyl, 3,6-diazabicyklo[3,1,0]heksanyl, (1R,5S)-3-azabicyklo[3,1,0]heksanyl, (1S,5R)-3-azabicyklo[3,2,0]heptanyl, 5-azaspiro[2,4]heptanyl, 2,6-diazaspiro[3,3]heptanyl, 2,5-diazaspiro[3,4]oktanyl, 2,6-diazaspiro[3,4]oktanyl, 2,7-diazaspiro[3,5]nonanyl, 2,7-diazaspiro[4,4]nonanyl, 2-azaspiro[4,5]decanyl, 2,8-diazaspiro[4,5]decanyl, 3,6-diazabicyklo[3,2,1]oktyl, 1,4-dihydroindeno[1,2-c]pyrazolyl, dihydropyranyl, dihydropyridinyl, dihydrokinolinyl, 8H-indeno[1,2-d]tiazolyl, tetrahydroimidazo[1,2-a]pyridinyl, pyridin-2(1H)-on, (1R,5S)-8-azabicyklo[3,2,1]oktyl og 8-azabicyklo[3,2,1]okt-2-enyl, hvor heterocyklyl eventuelt er substituert med 1, 2, 3, 4 eller 5 substituenter hver valgt fra R2, og

C9-10cykloalkyl er et mettet eller delvis umettet bicyklisk ringsystem eventuelt substituert med 1, 2, 3, 4 eller 5 substituenter hver valgt fra R2;

B er monocyklisk heterocyklyl, hvor heterocyklyl er et mettet eller delvis umettet ringsystem som har 1, 2 eller 3 heteroatomringelementer uavhengig valgt fra N, O eller S, hver eventuelt substituert med 1, 2, 3, 4 eller 5 substituenter hver valgt fra R4;

R1 er halogen, cyano, C1-4alkyl, halogen-C1-4alkyl, amino, C1-4alkyl-amino, (C1-4alkyl)2-amino, amino-C1-4alkyl, C1-4alkyl-amino-C1-4alkyl,

(C1-4alkyl)2-amino-C1-4alkyl, amino-karbonyl, C1-4alkyl-amino-karbonyl, (C1-4alkyl)2-amino-karbonyl, C1-4alkyl-amino-karbonyl-C1-4alkyl,

(C1-4alkyl)2-amino-karbonyl-C1-4alkyl, C1-4alkyl-karbonyl-amino,

C3-7cykloalkyl-C1-4alkoksy, C3-7cykloalkenyl, heteroaryl, heteroaryl-C1-4alkyl, heteroaryl-C1-4alkyl-amino, heteroaryl-C1-4alkyl-amino-karbonyl, heteroaryl-C1-4alkyl-karbonyl-amino, heteroaryl-C1-4alkyl-amino-karbonylC1-4alkyl, heteroaryl-C1-4alkyl-karbonyl-amino-C1-4alkyl, heterocyklyl, heterocyklyl-C1-4alkyl, heterocyklyl-C1-4alkoksy, fenyl eller fenyl-C1-4alkoksy, hvor:

heteroaryl er et monocyklisk, bicyklisk eller polycyklisk aromatisk karbonatomringstrukturradikal som har ett eller flere heteroatomer valgt fra O, S og N,

heterocyklyl er et mettet eller delvis umettet monocyklisk eller bicyklisk ringsystem som har 1, 2 eller 3 heteroatomringelementer valgt fra N, O og S og

hver forekomst av fenyl, heteroaryl eller heterocyklyl eventuelt er substituert med 1 eller 2 substituenter hver valgt fra R3;

R2 er halogen, cyano, okso, hydroksyl-imino, C1-4alkyl, halogen-C1-4alkyl, amino, C1-4alkyl-amino, (C1-4alkyl)2-amino, amino-C1-4alkyl, C1-4alkyl-amino-C1-4alkyl, (C1-4alkyl)2-amino-C1-4alkyl, amino-karbonyl, hydroksyl-C1-4alkyl, C1-4alkoksy, C1-4alkoksy-karbonyl, C2-4alkenyl, C3-7cykloalkyl eller heterocyklyl-C1-4alkyl, hvor:

heterocyklyl er et mettet eller delvis umettet monocyklisk eller bicyklisk ringsystem som har 1, 2 eller 3 heteroatomringelementer valgt fra N, O og S og

hver forekomst av heterocyklyl eventuelt er substituert med 1 eller 2 substituenter hver valgt fra R3;

R3 er halogen, hydroksyl, nitro, okso, hydroksyl-imino, C1-4alkyl, amino, C1-4alkyl-amino, (C1-4alkyl)2-amino, amino-C1-4alkyl, C1-4alkyl-amino-C1-4alkyl, (C1-4alkyl)2-amino-C1-4alkyl, amino-karbonyl, C1-4alkyl-amino-karbonyl, (C1-4alkyl)2-amino-karbonyl, C1-4alkyl-amino-karbonyl-C1-4alkyl,

(C1-4alkyl)2-amino-karbonyl-C1-4alkyl, C1-4alkyl-karbonyl-amino,

C1-4alkyl-karbonyl-amino-C1-4alkyl, hydroksyl-C1-4alkyl, C1-4alkyl-karbonyl, C1-4alkoksy, halogen-C1-4alkoksy, amino-C1-4alkoksy, hydroksyl-C1-4alkoksy, C1-4alkyl-C1-4alkoksy, C1-4alkyl-amino-C1-4alkoksy, (C1-4alkyl)2-amino-C1-4alkoksy, C1-4alkyl-karbonyl-amino-C1-4alkoksy, C1-4alkoksy-C1-4alkoksy, C1-4alkoksy-karbonyl, C1-4alkoksy-karbonyl-amino, C1-4alkoksy-karbonylamino-C1-4alkoksy, C2-4alkenyl, C2-4alkenyl-amino-karbonyl, C3-7cykloalkyl, C3-7cykloalkyl-C1-4alkoksy, C3-7cykloalkenyl, heteroaryl, heteroaryl-C1-4alkyl, heteroaryl-C1-4alkyl-amino, heteroaryl-C1-4alkyl-amino-karbonyl, heteroaryl-C1-4alkyl-karbonyl-amino, heteroaryl-C1-4alkyl-amino-karbonyl-C1-4alkyl, heteroaryl-C1-4alkyl-karbonyl-amino-C1-4alkyl, heterocyklyl, heterocyklyl-C1-4alkyl, fenyl eller fenyl-C1-4alkoksy;

R4 uavhengig er valgt fra halogen, C1-4alkyl, hydroksyl-C1-4alkyl, amino, C1-4alkyl-amino, (C1-4alkyl)2-amino eller hydroksyl-C1-4alkyl-amino; og

R5 er hydrogen, C1-4alkyl eller hydroksyl-C1-4alkyl;

hvor en form av forbindelsen er valgt fra gruppen bestående av en salt-, isotopolog-, racemat-, stereoisomer- og tautomerform derav.

2. Forbindelse eller en form derav for anvendelse ved behandling eller forbedring av Huntingtons sykdom ifølge krav 1, hvor

R1 er halogen, cyano, C1-4alkyl, halogen-C1-4alkyl, amino, C1-4alkyl-amino, (C1-4alkyl)2-amino, amino-C1-4alkyl, C1-4alkyl-amino-C1-4alkyl,

(C1-4alkyl)2-amino-C1-4alkyl, amino-karbonyl, C1-4alkyl-amino-karbonyl, C1-4alkyl-amino-karbonyl-C1-4alkyl, C1-4alkyl-karbonyl-amino,

C3-7cykloalkyl-C1-4alkoksy, C3-7cykloalkenyl, heteroaryl, heteroaryl-C1-4alkyl, heteroaryl-C1-4alkyl-amino, heteroaryl-C1-4alkyl-amino-karbonyl, heteroaryl-C1-4alkyl-karbonyl-amino, heteroaryl-C1-4alkyl-amino-karbonyl-C1-4alkyl, heteroaryl-C1-4alkyl-karbonyl-amino-C1-4alkyl, heterocyklyl, heterocyklyl-C1-4alkyl, heterocyklyl-C1-4alkoksy, fenyl eller fenyl-C1-4alkoksy, hvor:

heteroaryl er et monocyklisk, bicyklisk eller polycyklisk aromatisk karbonatomringstrukturradikal som har ett eller flere heteroatomer uavhengig valgt fra N, O og S,

heterocyklyl er et mettet eller delvis umettet monocyklisk eller bicyklisk ringsystem som har 1, 2 eller 3 heteroatomringelementer valgt fra N, O og S og

hver forekomst av fenyl, heteroaryl eller heterocyklyl eventuelt er substituert med 1 eller 2 substituenter hver valgt fra R3;

R2 er halogen, cyano, okso, hydroksyl-imino, C1-4alkyl, halogen-C1-4alkyl, amino, C1-4alkyl-amino, (C1-4alkyl)2-amino, amino-C1-4alkyl, amino-karbonyl, hydroksyl-C1-4alkyl, C1-4alkoksy, C1-4alkoksy-karbonyl, C2-4alkenyl,

C3-7cykloalkyl eller heterocyklyl-C1-4alkyl; og

R3 er halogen, hydroksyl, nitro, okso, hydroksyl-imino, C1-4alkyl, amino, C1-4alkyl-amino, (C1-4alkyl)2-amino, amino-C1-4alkyl, C1-4alkyl-amino-C1-4alkyl, (C1-4alkyl)2-amino-C1-4alkyl, amino-karbonyl, C1-4alkyl-amino-karbonyl, C1-4alkyl-amino-karbonyl-C1-4alkyl, C1-4alkyl-karbonyl-amino,

C3-7cykloalkyl-C1-4alkoksy, C3-7cykloalkenyl, heteroaryl, heteroaryl-C1-4alkyl, heteroaryl-C1-4alkyl-amino, heteroaryl-C1-4alkyl-amino-karbonyl, heteroaryl-C1-4alkyl-karbonyl-amino, heteroaryl-C1-4alkyl-amino-karbonyl-C1-4alkyl, heteroaryl-C1-4alkyl-karbonyl-amino-C1-4alkyl, heterocyklyl, heterocyklyl-C1-4alkyl, fenyl eller fenyl-C1-4alkoksy.

3. Forbindelse eller en form derav for anvendelse ved behandling eller forbedring av Huntingtons sykdom ifølge krav 1, hvor:

X er O, NH, N (CH3) eller en binding;

A er aryl, heteroaryl eller heterocyklyl,

hvor aryl er valgt fra gruppen bestående av:

hvor heteroaryl er valgt fra gruppen bestående av:

hvor heterocyclyl er valgt fra gruppen bestående av:

B er monocyklisk heterocyklyl valgt fra gruppen bestående av:

R1a og R1b er hver, hvor tillatt av tilgjengelig valenser, én eller flere substituenter hver valgt fra halogen, hydroksyl, cyano, C1-4alkyl, halogen-C1-4alkyl, amino, C1-4alkyl-amino, (C1-4alkyl)2-amino, amino-C1-4alkyl,

C1-4alkyl-amino-C1-4alkyl, (C1-4alkyl)2-amino-C1-4alkyl, amino-karbonyl, C1-4alkyl-amino-karbonyl, (C1-4alkyl)2-amino-karbonyl,

C1-4alkyl-amino-karbonyl-C1-4alkyl, (C1-4alkyl)2-amino-karbonyl-C1-4alkyl, C1-4alkyl-karbonyl-amino, C1-4alkyl-karbonyl-amino-C1-4alkyl,

hydroksyl-C1-4alkyl, C1-4alkyl-karbonyl, C1-4alkoksy, halogen-C1-4alkoksy, amino-C1-4alkoksy, hydroksyl-C1-4alkoksy, C1-4alkyl-C1-4alkoksy,

C1-4alkyl-amino-C1-4alkoksy, (C1-4alkyl)2-amino-C1-4alkoksy, C1-4alkyl-karbonylamino-C1-4alkoksy, C1-4alkoksy-C1-4alkoksy, C1-4alkoksy-karbonyl,

C1-4alkoksy-karbonyl-amino, C1-4alkoksy-karbonyl-amino-C1-4alkoksy,

C2-4alkenyl, C2-4alkenyl-amino-karbonyl, C3-7cykloalkyl, C3-7cykloalkyl-C1-4alkoksy, C3-7cykloalkenyl, heteroaryl, heteroaryl-C1-4alkyl,

heteroaryl-C1-4alkyl-amino, heteroaryl-C1-4alkyl-amino-karbonyl, heteroaryl-C1-4alkyl-karbonyl-amino, heteroaryl-C1-4alkyl-amino-karbonyl-C1-4alkyl, heteroaryl-C1-4alkyl-karbonyl-amino-C1-4alkyl, heterocyklyl, heterocyklyl-C1-4alkyl, heterocyklyl-C1-4alkoksy, fenyl eller fenyl-C1-4alkoksy, med det forbehold at når A er heteroaryl, er R1a og R1b ikke hydroksyl, hvor:

heteroaryl er et monocyklisk, bicyklisk eller polycyklisk aromatisk karbonatomringstrukturradikal som har ett eller flere heteroatomer uavhengig valgt fra N, O og S,

heterocyklyl er et mettet eller delvis umettet monocyklisk eller bicyklisk ringsystem som har 1, 2 eller 3 heteroatomringelementer valgt fra N, O og S og

hver forekomst av fenyl, heteroaryl eller heterocyklyl eventuelt er substituert med 1 eller 2 substituenter hver valgt fra R3;

R2a, R2b og R2c er hver, hvor tillatt av tilgjengelig valenser, én eller flere substituenter hver valgt fra halogen, cyano, okso, hydroksyl-imino, C1-4alkyl, halogen-C1-4alkyl, amino, C1-4alkyl-amino, (C1-4alkyl)2-amino, amino-C1-4alkyl, C1-4alkyl-amino-C1-4alkyl, (C1-4alkyl)2-amino-C1-4alkyl, amino-karbonyl, hydroksyl-C1-4alkyl, C1-4alkoksy, C1-4alkoksy-karbonyl, C2-4alkenyl,

C3-7cykloalkyl eller heterocyklyl-C1-4alkyl, hvor:

heterocyklyl er et mettet eller delvis umettet monocyklisk eller bicyklisk ringsystem som har 1, 2 eller 3 heteroatomringelementer valgt fra N, O og S, og

hver forekomst av heterocyklyl er eventuelt substituert med 1 eller 2 substituenter hver valgt fra R3;

R4a, R4b, R4c, R4d, R4e, R4f og R4g er uavhengig valgt fra halogen, C1-4alkyl, hydroksyl-C1-4alkyl, amino, C1-4alkyl-amino, (C1-4alkyl)2-amino eller hydroksyl-C1-4alkyl-amino.

4. Forbindelse eller en form derav for anvendelse ved behandling eller forbedring av Huntingtons sykdom ifølge krav 1, hvor forbindelsen er valgt fra gruppen bestående av:

6-(naftalen-2-yl)-N-(2,2,6,6-tetrametylpiperidin-4-yl)pyridazin-3-amin

6-(benzo[b]tiofen-2-yl)-N-metyl-N-(2,2,6,6-tetrametylpiperidin-4-yl)pyridazin-3-amin

2-(6-(2,2,6,6-tetrametylpiperidin-4-yl-amino)-pyridazin-3-yl)fenol

2-(6-(metyl-(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)benzo[b]-tiofen-5-karbonitril

6-(kinolin-3-yl)-N-(2,2,6,6-tetrametylpiperidin-4-yl)pyridazin-3-amin

3-(benzo[b]-tiofen-2-yl)-6-(2,2,6,6-tetrametylpiperidin-4-yl-oksy)pyridazin 2-(6-(metyl-(2,2,6,6-tetrametylpiperidin-4-yl)amino)-pyridazin-3-yl)fenol 6-(6-(metyl-(2,2,6,6-tetrametylpiperidin-4-yl)amino)-pyridazin-3-yl)naftalen-2-ol

6-(benzo[b]-tiofen-2-yl)-N-(2,2,6,6-tetrametylpiperidin-4-yl)pyridazin-3-amin 7-(6-((2,2,6,6-tetrametylpiperidin-4-yl)oksy)pyridazin-3-yl)isokinolin

6-(6-((2,2,6,6-tetrametylpiperidin-4-yl)oksy)pyridazin-3-yl)isokinolin

N-metyl-6-(kinolin-7-yl)-N-(2,2,6,6-tetrametylpiperidin-4-yl)pyridazin-3-amin N-metyl-6-(kinolin-6-yl)-N-(2,2,6,6-tetrametylpiperidin-4-yl)pyridazin-3-amin 6-(isokinolin-7-yl)-N-metyl-N-(2,2,6,6-tetrametylpiperidin-4-yl)pyridazin-3-amin

6-(isokinolin-6-yl)-N-metyl-N-(2,2,6,6-tetrametylpiperidin-4-yl)pyridazin-3-amin

6-(imidazo[1,2-a]pyridin-6-yl)-N-metyl-N-(2,2,6,6-tetrametylpiperidin-4-yl)pyridazin-3-amin

metyl-(6-kinoksalin-2-yl-pyridazin-3-yl)-(2,2,6,6-tetrametylpiperidin-4-yl)-amin

metyl-(6-kinolin-3-yl-pyridazin-3-yl)-(2,2,6,6-tetrametylpiperidin-4-yl)-amin N-metyl-6-(ftalazin-6-yl)-N-(2,2,6,6-tetrametylpiperidin-4-yl)pyridazin-3-amin 6-(benzo[c][1,2,5]oksa-diazol-5-yl)-N-(2,2,6,6-tetrametylpiperidin-4-yl)pyridazin-3-amin

6-(benzo[d]tiazol-5-yl)-N-(2,2,6,6-tetrametylpiperidin-4-yl)pyridazin-3-amin 6-(2-metylbenzo-[d]oksazol-6-yl)-N-(2,2,6,6-tetrametylpiperidin-4-yl)pyridazin-3-amin

3-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)naftalen-2-ol

5-klor-2-(6-(metyl(1,2,2,6,6-pentametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

3-(6-(2,2,6,6-tetrametylpiperidin-4-yl-amino)pyridazin-3-yl)naftalen-2-ol 5-klor-2-(6-(1,2,2,6,6-pentametylpiperidin-4-ylamino)pyridazin-3-yl)fenol 4-hydroksy-3-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)benzonitril

3-(6-((2,2,6,6-tetrametylpiperidin-4-yl)oksy)pyridazin-3-yl)naftalen-2-ol 2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-4-(trifluormetyl)fenol

2-fluor-6-(6-(metyl-(2,2,6,6-tetrametylpiperidin-4-yl)-amino)-pyridazin-3-yl)fenol

3,5-dimetoksy-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

4,5-dimetoksy-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

5-metoksy-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

4,5-difluor-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

5-fluor-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol 3-hydroksy-4-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)benzonitril

1-allyl-6-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)naftalen-2-ol

6-(benzo[b]tiofen-2-yl)-N-(1,2,2,6,6-pentametylpiperidin-4-yl)pyridazin-3-amin

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)fenol

5-(5-metyl-oksazol-2-yl)-2-(6-(metyl-(2,2,6,6-tetrametylpiperidin-4-yl)-amino)-pyridazin-3-yl)fenol

5-(4-(hydroksymetyl)-1H-pyrazol-1-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

5-(1H-imidazol-1-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

5-(4-amino-1H-pyrazol-1-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1H-pyrazol-4-yl)fenol

5-(3-amino-1H-pyrazol-1-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1-(2-morfolino-etyl)-1H-pyrazol-4-yl)fenol

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1-metyl-1H-pyrazol-4-yl)fenol

5-(5-amino-1H-pyrazol-1-yl)-2-(6-(metyl-(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-4-(1H-pyrazol-1-yl)fenol

2-((6-((2-hydroksy-etyl)-(2,2,6,6-tetrametylpiperidin-4-yl)-amino)-pyridazin-3-yl)-5-pyrazol-1-yl)fenol

2-(6-(piperidin-4-yloksy)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)fenol

2-(6-(((2S,4R,6R)-2,6-dimetylpiperidin-4-yl)oksy)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)fenol

2-(6-((-2,6-dimetylpiperidin-4-yl)oksy)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)fenol 5-(1H-pyrazol-1-yl)-2-(6-(pyrrolidin-3-yl-oksy)pyridazin-3-yl)fenol

2-(6-(((2S,4S)-2-metylpiperidin-4-yl)oksy)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)fenol

2-(6-((3-fluorpiperidin-4-yl)oksy)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)fenol 2-(6-(1,2,2,6,6-pentametyl-piperidin-4-yl-oksy)-pyridazin-3-yl)-5-(1H-pyrazol-1-yl)fenol

5-1H-pyrazol-1-yl-2-(6-(2,2,6,6-tetrametylpiperidin-4-yl-oksy)-pyridazin-3-yl)fenol

5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetrametylpiperidin-4-yl)oksy)pyridazin-3-yl)fenol

2-(6-piperazin-1-yl-pyridazin-3-yl)-5-(1H-pyrazol-1-yl)fenol

3-(6-(azetidin-3-ylamino)-pyridazin-3-yl)naftalen-2-ol

2-(6-(azetidin-3-ylamino)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)fenol

2-(6-(3,5-dimetylpiperazin-1-yl)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)fenol 2-(6-(1,4-diazepan-1-yl)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)fenol

2-(6-(4-(2-hydroksyetyl)piperazin-1-yl)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)fenol 2-(6-(3-(hydroksymetyl)piperazin-1-yl)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)fenol 2-(6-(4-amino-4-metylpiperidin-1-yl)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)fenol 2-(6-(3-(dimetylamino)piperidin-1-yl)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)fenol 2-(6-(1,2,2,6,6-pentametylpiperidin-4-ylamino)-pyridazin-3-yl)-5-1H-pyrazol-1-yl-fenol

2-(6-(3,3-dimetylpiperazin-1-yl)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)fenol 3-(6-(piperazin-1-yl)pyridazin-3-yl)naftalen-2,7-diol

5-(1H-pyrazol-1-yl)-2-(6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)fenol 2-(6-piperidin-4-yl-pyridazin-3-yl)-5-1H-pyrazol-1-yl-fenol

3-(6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)naftalen-2-ol

3-(6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)naftalen-2,7-diol

3-(6-(2,2,6,6-tetrametyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)naftalen-2,7-diol

3-(6-(1-metyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)naftalen-2,7-diol 3-(6-(piperidin-4-yl)pyridazin-3-yl)naftalen-2,7-diol

3-(6-((2,2,6,6-tetrametylpiperidin-4-yl)oksy)pyridazin-3-yl)naftalen-2,7-diol 3-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)naftalen-2,7-diol

7-(3-amino-propoksy)-3-(6-(metyl-(2,2,6,6-tetrametylpiperidin-4-yl)-amino)-pyridazin-3-yl)naftalen-2-ol

N-(3-((7-hydroksy-6-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)naftalen-2-yl)oksy)propyl)acetamid

7-(3-hydroksypropoksy)-3-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)naftalen-2-ol

7-(3-metoksypropoksy)-3-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)naftalen-2-ol

7-(2-morfolinoetoksy)-3-(6-((2,2,6,6-tetrametylpiperidin-4-yl)oksy)pyridazin-3-yl)naftalen-2-ol

3-(6-(piperidin-4-ylmetyl)pyridazin-3-yl)naftalen-2-ol

5-(1H-pyrazol-1-yl)-2-(6-((2,2,6,6-tetrametylpiperidin-4-yl)metyl)pyridazin-3-yl)fenol

3-metoksy-2-(6-(metyl(2,2,6-trimetylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(5-metyloksazol-2-yl)fenol

2-(6-((6S)-6-((S)-1-hydroksyetyl)-2,2-dimetylpiperidin-4-yloksy)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)fenol

7-hydroksy-6-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-2-naftonitril

3-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-7-(piperidinylmetyl)naftalen-2-ol

3-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-7-(pyrrolidinylmetyl)naftalen-2-ol

1-brom-6-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)naftalen-2,7-diol

1-klor-6-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)naftalen-2,7-diol

7-metoksy-3-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)naftalen-2-ol

7-metoksy-3-(6-(metyl(1,2,2,6,6-pentametylpiperidin-4-yl)amino)pyridazin-3-yl)naftalen-2-ol

7-(3,6-dihydro-2H-pyran-4-yl)-3-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)naftalen-2-ol

3-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-7-(tetrahydro-2H-pyran-4-yl)naftalen-2-ol

7-(difluormetyl)-3-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)naftalen-2-ol

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1H-pyrazol-4-yl)benzen-1,3-diol

3-metoksy-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1H-pyrazol-4-yl)fenol

5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-3-(trifluormetoksy)fenol

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1-metyl-1H-pyrazol-4-yl)-3-(trifluormetoksy)fenol

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1H-pyrazol-4-yl)-3-(trifluormetoksy)fenol

4-(3-hydroksy-4-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(trifluormetoksy)fenyl)-1-metylpyridin-2(1H)-on

3-metoksy-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1-metyl-1H-pyrazol-4-yl)fenol

3-metoksy-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl)fenol

3-metoksy-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(pyridin-3-yl)fenol

5-(1-cyklopentyl-1H-pyrazol-4-yl)-3-metoksy-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

3’,5-dimetoksy-4-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-(1,1'-bifenyl)-3-ol

3-(benzyloksy)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(5-metyloksazol-2-yl)fenol

3-etoksy-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(5-metyloksazol-2-yl)fenol

3-(cyklopropylmetoksy)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)-pyridazin-3-yl)-5-(5-metyloksazol-2-yl)fenol

5-klor-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol 5-(1H-pyrazol-1-yl)-2-(6-((2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

3-hydroksy-4-(6-((2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)benzonitril

2-(6-((2,2-dimetylpiperidin-4-yl)oksy)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)fenol 2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-4-(1H-pyrazol-4-yl)fenol

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)fenol

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)fenol

4-(1H-indol-2-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

4-(cyklopent-1-en-1-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-4-(1H-pyrazol-3-yl)fenol

4-(4-hydroksy-3-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenyl)pyridin-2-ol

4-(4-hydroksy-3-(6-((2,2,6,6-tetrametylpiperidin-4-yl)oksy)pyridazin-3-yl)fenyl)-1-metylpyridin-2(1H)-on

4-(4-hydroksy-3-(6-((2,2,6,6-tetrametylpiperidin-4-yl)oksy)pyridazin-3-yl)fenyl)pyridin-2-ol

5-(1H-indazol-7-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

4-klor-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1H-pyrazol-4-yl)fenol

4-fluor-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1H-pyrazol-4-yl)fenol

5-fluor-4-(1H-imidazol-4-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

5-fluor-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-4-(1H-pyrazol-4-yl)fenol

5-fluor-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-4-(1H-pyrazol-5-yl)fenol

4-hydroksy-3-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-N-((1-metyl-1H-pyrazol-4-yl)metyl)benzamid

4-(4-(hydroksymetyl)-1H-pyrazol-1-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetrametylpiperidin-4-yl)metyl)pyridazin-3-yl)fenol

6-(3-(benzyloksy)isokinolin-6-yl)-N-metyl-N-(2,2,6,6-tetrametylpiperidin-4-yl)pyridazin-3-amin

6-(1-(benzyloksy)isokinolin-7-yl)-N-metyl-N-(2,2,6,6-tetrametylpiperidin-4-yl)pyridazin-3-amin

3-fluor-5-(2-metoksypyridin-4-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

4-(3-fluor-5-hydroksy-4-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenyl)pyridin-2(1H)-on

4-(3-fluor-5-hydroksy-4-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenyl)-1-metylpyridin-2(1H)-on

5-(3-fluor-5-hydroksy-4-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenyl)-1-metylpyridin-2(1H)-on

3-fluor-5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetrametylpiperidin-4-yl)oksy)pyridazin-3-yl)fenol

5-klor-3-fluor-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

3-fluor-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1H-pyrazol-4-yl)fenol

3-fluor-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1-metyl-1H-pyrazol-4-yl)fenol

5-(5-metoksypyridin-3-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

5-(3-hydroksy-4-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenyl)pyridin-2-ol

4-(3-hydroksy-4-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenyl)pyridin-2-ol

5-(6-metoksypyridin-3-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

5-(3-hydroksy-4-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenyl)-1-metylpyridin-2(1H)-on

4-(3-hydroksy-4-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenyl)-1-metylpyridin-2(1H)-on

5-(2-metoksypyridin-4-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

4-(3-hydroksy-4-(6-((2,2,6,6-tetrametylpiperidin-4-yl)oksy)pyridazin-3-yl)fenyl)pyridin-2-ol

5-(6-(dimetylamino)pyridin-3-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

4-(3-hydroksy-4-(6-((2,2,6,6-tetrametylpiperidin-4-yl)oksy)pyridazin-3-yl)fenyl)-1-metylpyridin-2(1H)-on

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(pyrimidin-5-yl)fenol

5-(3-hydroksy-4-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenyl)pyridin-3-ol

1-cyklopropyl-4-(3-hydroksy-4-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenyl)pyridin-2(1H)-on

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)fenol

5-(3,6-dihydro-2H-pyran-4-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

5-(imidazo[1,5-a]pyridin-7-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

5-(imidazo[1,2-a]pyridin-7-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(2-metylpyridin-4-yl)fenol

5-(1H-imidazol-2-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

5-(1H-imidazol-4-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

5-(imidazo[1,2-a]pyrazin-3-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-3-yl)fenol

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(4-metyl-1H-imidazol-2-yl)fenol

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1-metyl-1H-imidazol-4-yl)fenol

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1-metyl-1H-imidazol-5-yl)fenol

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(4-nitro-1H-imidazol-2-yl)fenol

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(2-metyl-1H-imidazol-4-yl)fenol

5-(1,2-dimetyl-1H-imidazol-4-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenol

1-(3-hydroksy-4-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenyl)-1H-pyrazol-4-karboksamid

5-(1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetrametylpiperidin-4-yl)amino]pyridazin-3-yl}fenol

5-(1-metyl-1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetrametylpiperidin-4-yl)oksy]pyridazin-3-yl}fenol

5-(5-metyl-1H-pyrazol-4-yl)-2-{6-[metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino]pyridazin-3-yl}fenol

5-(1H-imidazol-1-yl)-2-{6-[(2,2,6,6-tetrametylpiperidin-4-yl)oksy]pyridazin-3-yl}fenol

5-(5-metyl-1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetrametylpiperidin-4-yl)oksy]pyridazin-3-yl}fenol

2-{6-[metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino]pyridazin-3-yl}-5-(4-nitro-1H-pyrazol-1-yl)fenol

5-(4-amino-1H-pyrazol-1-yl)-2-{6-[(2,2,6,6-tetrametylpiperidin-4-yl)oksy]pyridazin-3-yl}fenol

2-[6-(1-metyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)fenol

5-(4-nitro-1H-pyrazol-1-yl)-2-{6-[(2,2,6,6-tetrametylpiperidin-4-yl)oksy]pyridazin-3-yl}fenol

5-(1H-pyrazol-4-yl)-2-[6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]fenol 2-[6-(1-etyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)fenol

2-{6-[metyl(piperidin-4-yl)amino]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)fenol 2-[6-(piperidin-4-ylamino)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)fenol

2-[6-(piperidin-4-yloksy)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)fenol

2-{6-[(2,6-dimetylpiperidin-4-yl)oksy]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)fenol 3-[4-(1-metyl-1H-pyrazol-4-yl)tiofen-2-yl]-6-[(2,2,6,6-tetrametylpiperidin-4-yl)oksy]pyridazin

3-fluor-4-{6-[metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino]pyridazin-3-yl}fenol

2-{6-[(2,6-dimetylpiperidin-4-yl)oksy]pyridazin-3-yl}-5-(1H-pyrazol-1-yl)fenol N-metyl-6-(2-metyl-2H-indazol-5-yl)-N-(2,2,6,6-tetrametylpiperidin-4-yl)pyridazin-3-amin

2-metyl-5-{6-[(2,2,6,6-tetrametylpiperidin-4-yl)oksy]pyridazin-3-yl}-2H-indazol

N-metyl-6-(2-metylpyrazolo[1,5-a]pyridin-3-yl)-N-(2,2,6,6-tetrametylpiperidin-4-yl)pyridazin-3-amin

6-{6-[(2,2,6,6-tetrametylpiperidin-4-yl)oksy]pyridazin-3-yl}imidazo[1,2-a]pyridin

3-[5-(1H-pyrazol-4-yl)tiofen-2-yl]-6-[(2,2,6,6-tetrametylpiperidin-4-yl)oksy]pyridazin

3-[5-(1-metyl-1H-pyrazol-4-yl)tiofen-2-yl]-6-[(2,2,6,6-tetrametylpiperidin-4-yl)oksy]pyridazin

3-[4-(1H-pyrazol-4-yl)tiofen-2-yl]-6-[(2,2,6,6-tetrametylpiperidin-4-yl)oksy]pyridazin

5-(3,5-dimetyl-1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetrametylpiperidin-4-yl)oksy]pyridazin-3-yl}fenol

3-metoksy-4-{6-[(2,2,6,6-tetrametylpiperidin-4-yl)oksy]pyridazin-3-yl}fenol 4-{6-[(2,2,6,6-tetrametylpiperidin-4-yl)oksy]pyridazin-3-yl}benzen-1,3-diol og 2-(1H-pyrazol-4-yl)-4-{6-[(2,2,6,6-tetrametylpiperidin-4-yl)oksy]pyridazin-3-yl}pyrimidin-5-amin;

hvor en form av forbindelsen er valgt fra gruppen bestående av en salt-, isotopolog-, racemat-, stereoisomer- og tautomerform derav.

5. Forbindelse eller en form derav for anvendelse ved behandling eller forbedring av Huntingtons sykdom ifølge krav 4, hvor forbindelsen er et forbindelsessalt valgt fra gruppen bestående av:

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-4-(trifluormetyl)fenolhydroklorid

2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-4-(1H-pyrazol-1-yl)fenolhydroklorid

3-(6-(piperazin-1-yl)pyridazin-3-yl)naftalen-2,7-dioltrifluoracetat

3-(6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)naftalen-2,7-dioltrifluoracetat

3-(6-(1-metyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)naftalen-2,7-dioltrifluoracetat

3-(6-(piperidin-4-yl)pyridazin-3-yl)naftalen-2,7-dioltrifluoracetat

3-fluor-5-(2-metoksypyridin-4-yl)-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenolhydroklorid

4-(3-fluor-5-hydroksy-4-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenyl)pyridin-2(1H)-onhydroklorid

4-(3-fluor-5-hydroksy-4-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenyl)-1-metylpyridin-2(1H)-onhydroklorid

5-(3-fluor-5-hydroksy-4-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenyl)-1-metylpyridin-2(1H)-onhydroklorid

3-fluor-5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetrametylpiperidin-4-yl)oksy)pyridazin-3-yl)fenolhydroklorid

5-klor-3-fluor-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)fenolhydroklorid

3-fluor-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1H-pyrazol-4-yl)fenolhydroklorid

3-fluor-2-(6-(metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1-metyl-1H-pyrazol-4-yl)fenolhydroklorid

5-(1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetrametylpiperidin-4-yl)amino]pyridazin-3-yl}fenolhydroklorid

2-{6-[metyl(2,2,6,6-tetrametylpiperidin-4-yl)amino]pyridazin-3-yl}-5-(4-nitro-1H-pyrazol-1-yl)fenoldihydroklorid

2-[6-(1-metyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)fenoltrihydroklorid

5-(1H-pyrazol-4-yl)-2-[6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]fenoltrihydroklorid

2-[6-(1-etyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)fenoltrihydroklorid

2-{6-[metyl(piperidin-4-yl)amino]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)fenol tetrahydroklorid

2-[6-(piperidin-4-ylamino)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)fenol tetrahydroklorid

2-{6-[(2,6-dimetylpiperidin-4-yl)oksy]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)fenoltrihydroklorid

3-[5-(1H-pyrazol-4-yl)tiofen-2-yl]-6-[(2,2,6,6-tetrametylpiperidin-4-yl)oksy]pyridazinhydroklorid og

3-[4-(1H-pyrazol-4-yl)tiofen-2-yl]-6-[(2,2,6,6-tetrametylpiperidin-4-yl)oksy]pyridazinhydroklorid;

hvor en form av forbindelsessaltet er valgt fra gruppen bestående av en isotopolog-, racemat-, stereoisomer og tautomerform derav.

6. Forbindelse eller form derav for anvendelse ved behandling eller forbedring av Huntingtons sykdom ifølge et hvilket som helst av kravene 1-5 eller 8-11, hvor den effektive mengden av forbindelsen er i intervallet fra 0,001 mg/kg/dag til 500 mg/kg/dag.

7. Forbindelse eller form derav for anvendelse ved behandling eller forbedring av Huntingtons sykdom ifølge et hvilket som helst av kravene 1-6 eller 8-11, hvor sammensetningen er blandet med ett eller flere farmasøytisk akseptable hjelpestoff(er) i en farmasøytisk sammensetning.

8. Forbindelse, eller form derav, for anvendelse ved behandling eller forbedring av Huntingtons sykdom (HD) hos et individ med behov derav, hvor forbindelsen, eller formen derav, er valgt fra gruppen bestående av